DIP
CRSP icon

DT Investment Partners’s CRISPR Therapeutics CRSP Stock Holding History

DT Investment Partners’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$600 Hold
11
– – ﹤0.01% 500
2026
Q1 		$524 Hold
11
– – ﹤0.01% 508
2025
Q4 		$577 Hold
11
– – ﹤0.01% 532
2025
Q3 		$713 Hold
11
– – ﹤0.01% 524
2025
Q2 		$536 Hold
11
– – ﹤0.01% 522
2025
Q1 		$375 Hold
11
– – ﹤0.01% 544
2024
Q4 		$433 Hold
11
– – ﹤0.01% 547
2024
Q3 		$517 Buy
+11
New +$558 ﹤0.01% 618

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

DT Investment Partners's CRSP Position: Q2 2026 in Review

DT Investment Partners held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 11 shares worth $600. The position accounts for ﹤0.01% of the portfolio, ranked #500.

DT Investment Partners first reported a position in CRSP in Q3 2024 and has held it in 8 quarters since. The position peaked at $713 in Q3 2025. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • DT Investment Partners held 11 shares of CRISPR Therapeutics worth $600 as of Q2 2026.
  • DT Investment Partners left its CRISPR Therapeutics share count unchanged in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of DT Investment Partners's portfolio in Q2 2026, its #500 holding.
  • DT Investment Partners first reported a position in CRISPR Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • DT Investment Partners's CRISPR Therapeutics position peaked at $713 in Q3 2025.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on DT Investment Partners's 13F filing for Q2 2026, filed 27 Jul 2026.